Navigation Links
DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
Date:8/4/2011

top-line results from a Phase II clinical trial conducted by King for the treatment of chronic low back pain.  The primary efficacy endpoint for the trial was not met.  We and Pfizer are continuing to analyze these data and will work together to determine next steps for ELADUR.ELADUR is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to three days from a single application.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website at www.durect.com/wt/durect/page_name/Publications.


  • TRANSDUR-Sufentanil.  In recent months, we have had discussions with the FDA and regulatory agencies in several major European countries to better understand development requirements for U.S. and European approval in furtherance of our development plans for TRANSDUR-Sufentanil.  We continue discussions with potential partners regarding licensing development and commercialization rights to this program to which we hold worldwide rights.TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to seven days from a single application.


  • ORADUR-ADHD Program.  In the second quarter of 2011, we and Orient Pharma completed a Phase I pharmacokinetic study with multiple formulations.  We are continuing to optimize the formulation and are planning next steps in our ORADUR-ADHD program.


  • Relday™ (Risperidone Program).  In July 2011, we signed a development and license agreement with Zogenix to develop Relday, a product candidate targeting the antipsy
    '/>"/>


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    2. DURECT to Present at the Jefferies Healthcare Conference
    3. DURECT Announces Resignation of Chief Medical Officer
    4. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
    5. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
    6. DURECT to Present at Cowen and Company Health Care Conference
    7. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
    8. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
    9. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
    10. DURECT to Present at the BIO CEO & Investor Conference
    11. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
    (Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
    (Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
    Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
    ... Sheets: SIMH)  In a shrewd execution of its business ... with Keith Houlihan, Co-founder and President of Sanomedics ... signing of a letter of intent to acquire a ... platform in sleep apnea treatment services.  The targeted acquisition ...
    ... Dec. 12, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and infectious diseases, announced today that Dr. J. Joseph Kim, ... at the Oppenheimer 22nd Annual Healthcare Conference taking place December ... Inovio Presentation December 13 10:50 am ET ...
    Cached Medicine Technology:Sanomedics Signs Letter of Intent to Acquire Large Sleep Disorder Service Based Operation 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3
    (Date:12/24/2014)... a famous bamboo flooring company offering bamboo flooring products ... its multiple layer bamboo panel board collection , and ... Bamboo panel is the product made from 100 percent ... features high quality selective bamboo and eco-friendly adhesives that ... consists of multiple layers of bamboo. , According to ...
    (Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
    (Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
    (Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Researchers say ... cells that develop into eggs and sperm. While ... this is the first time that these types of ... produced efficiently using human stem cells, according to the ... "The creation of primordial germ cells is one of ...
    (Date:12/24/2014)... -- A lab technician with the U.S. Centers for ... the Ebola virus in an agency laboratory in Atlanta ... other lab workers are being checked for possible exposure, ... exposure occurred Monday when CDC scientists doing research on ... virus to another CDC lab in the same building, ...
    Breaking Medicine News(10 mins):Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
    ... MONDAY, Dec. 5 (HealthDay News) -- There,s been a large increase ... States since 2002, a trend that may help ease concerns about ... analyzed national data and found that the number of RNs aged ... fell to fewer than 110,000 by 1991 and remained low for ...
    ... University of Kentucky researchers recently received a $225,000 grant ... The grant gives the team $225,000 for the ... that could total $675,000. It is funded by the ... Rural Cancer Prevention Center. Published studies have shown ...
    ... By Serena Gordon HealthDay Reporter , MONDAY, Dec. ... with asthma is currently using a preventive medication, according to ... percent of kids during the late 1980s. Preventive ... up, and guidelines from the U.S. National Asthma Education and ...
    ... -- Teenagers with autism who also have epilepsy often ... The combination means that certain behaviors common among autistic ... of their faces -- could increase their risk for ... 14 percent of children with epilepsy, the rate jumps ...
    ... and non-obese children found that low vitamin D levels are ... risk factors for type 2 diabetes. This study was accepted ... Endocrinology & Metabolism (JCEM). High rates of vitamin ... studies have linked low vitamin D levels to cardiovascular disease ...
    ... , SATURDAY, Dec. 3 (HealthDay News) -- Seizures ... during menstruation or ovulation, researchers have found. ... at the University of California, Irvine, examined the trend ... among a group of women aged 19 to 50. ...
    Cached Medicine News:Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:Low vitamin D levels may contribute to development of Type 2 diabetes 2Health News:Epileptic Seizures May Worsen During Menstrual Cycle 2
    ... Cutter has application in multiple open or ... resection, and/or creation of anastomoses and can ... buttressing materials such as bovine pericardium., ... a total of eight firings. Different cartridges ...
    ... in Open Procedures with Compact Endoscopic ... Compact-Flex45 No-Knife Articulating Linear Staplers is ... line for open surgical procedures. It ... blue cartridge, a thick-tissue green cartridge, ...
    ... ENDO CLIP MultApplier reusable clip applier is designed ... loading unit, each of which contains eight (8) ... shaft of the instrument is approximately 12.8" (32.5 ... and use through an appropriately sized Auto Suture ...
    ENDO CLIP II ML, 10 mm Pistol Grip Single Use Clip Applier with Medium - Large Super Interlock Titanium Clips...
    Medicine Products: